GSK to buy Nuvalent, maker of targeted cancer drugs, for $10.6B The move will grow the U.K. firm’s work in oncology, particularly in lung cancer By Andrew JosephJune 9, 2026 Europe Correspondent

https://www.statnews.com/2026/06/09/gsk-nuvalent-acquistion-oncology-lung-cancer-zidesamtinib-neladalkib/